CCLI. Bronchiectasis Treatment Antibiotics. Charles Haworth. Physician / Patient Conference, Georgetown University, May 2017
|
|
|
- Aubrey Wells
- 6 years ago
- Views:
Transcription
1 Physician / Patient Conference, Georgetown University, May 2017 Bronchiectasis Treatment Antibiotics Charles Haworth CCLI Cambridge Centre for Lung Infection
2 Disclosures Educational talks and / or consultancy for: Aradigm, Chiesi, Gilead, Insmed, Novartis, Horizon, TEVA, Zambon, Vertex.
3 Development of bronchiectasis - vicious cycle Problems with muco-ciliary clearance Problems with Immune response Inflammatory Insult
4 Development of bronchiectasis - vicious cycle Problems with muco-ciliary clearance Problems with Immune response Inflammatory Insult Bronchial wall inflammation
5 Development of bronchiectasis - vicious cycle Problems with muco-ciliary clearance Problems with Immune response Inflammatory Insult Bronchial wall inflammation Disordered mucociliary clearance / obstruction
6 Development of bronchiectasis - vicious cycle Problems with muco-ciliary clearance Problems with Immune response Inflammatory Insult Bronchial wall inflammation Disordered mucociliary clearance / obstruction Chronic / recurrent infection
7 Development of bronchiectasis - vicious cycle Problems with muco-ciliary clearance Problems with Immune response Inflammatory Insult Bronchial wall inflammation Bronchial wall damage Disordered mucociliary clearance / obstruction Chronic / recurrent infection
8 Development of bronchiectasis - vicious cycle Problems with muco-ciliary clearance Problems with Immune response Inflammatory Insult
9 Development of bronchiectasis - vicious cycle Bacterial load (CFU/ml) Bacterial load (CFU/ml) Chalmers AJRCCM 2012
10 Common bacteria in people with bronchiectasis NTM Current: 1.7% Previous: 3.1% 76% received treatment Pseudomonas aeruginosa Current: 18.5% Previous:10.2% 69% received eradication treatment 22.5% of patients did not provide sputum samples (similar to previous work)
11 Antibiotic use in bronchiectasis Exacerbation treatment Chronic suppression Eradication
12 Antibiotic use in bronchiectasis Exacerbation treatment Chronic suppression Eradication
13 Exacerbations Essential to distinguish between steady state and exacerbation Acute exacerbations Deterioration in symptoms over days cough frequency sputum volume / purulence / viscosity chest tightness / wheeze / breathlessness Chest ache, streaky haemoptysis, temperatures
14 Exacerbation Treatment Important management principals: Higher doses of an antibiotic are often more effective than lower doses of the same antibiotic Hill SL Thorax 1986
15 Exacerbation Treatment Important management principals: Expert consensus is that bronchiectasis exacerbations should be treated with 14 days of antibiotics. Pasteur Thorax 2010 Polverino Eur Resp J In press
16 Exacerbation Treatment Antibiotic treatment choices should be guided by previous sputum culture results
17 Exacerbation Treatment Oral antibiotics: H. influenzae, S. pneumoniae Amoxicillin or Doxycycline β-lactamase producing strains Co-Amoxiclav P. aeruginosa Ciprofloxacin MRSA Rifampicin and Fucidic acid
18 Exacerbation Treatment Intravenous antibiotics: H. influenzae, S. pneumoniae, M. catarrhalis Piperacillin/Tazobactam Cefuroxime Ertapenem
19 Exacerbation Treatment Intravenous antibiotics for P. aeruginosa: Dual therapy Reduce development of resistance Potential for synergy Synergy with β-lactams & aminoglycosides in CF Individuals with chronic P. aeruginosa IV azlocillin + tobramycin or placebo Initial outcomes comparable. P. aeruginosa density decreased Time to next hospitalisation increased
20 Exacerbation Treatment Intravenous antibiotics for P. aeruginosa: Dual therapy Reduce development of resistance Potential for synergy Synergy with β-lactams & aminoglycosides in CF Individuals with chronic P. aeruginosa IV azlocillin + tobramycin or placebo Initial outcomes comparable. P. aeruginosa density decreased Time to next hospitalisation increased
21 Exacerbation Treatment Intravenous antibiotics for P. aeruginosa: Dual therapy Reduce development of resistance Potential for synergy Synergy with β-lactams & aminoglycosides in CF Individuals with chronic P. aeruginosa IV azlocillin + tobramycin or placebo Initial outcomes comparable. P. aeruginosa density decreased Time to next hospitalisation increased Smith AL J Pediatr 1999
22 Exacerbation Treatment Intravenous antibiotics for P. aeruginosa: Dual therapy Reduce development of resistance Potential for synergy Synergy with β-lactams & aminoglycosides in CF Individuals with chronic P. aeruginosa IV azlocillin + tobramycin or placebo Initial outcomes comparable. P. aeruginosa density decreased Time to next hospitalisation increased Smith AL J Pediatr 1999
23 Exacerbation Treatment Intravenous antibiotics for P. aeruginosa: Dual therapy Reduce development of resistance Potential for synergy Synergy with β-lactams & aminoglycosides in CF Individuals with chronic P. aeruginosa IV azlocillin + tobramycin or placebo Initial outcomes comparable. P. aeruginosa density decreased Time to next hospitalisation increased Dual Therapy Group Smith AL J Pediatr 1999
24 Antibiotic use in Bronchiectasis Exacerbation treatment Chronic suppression Eradication
25 Chronic bacterial suppression Commonly prescribed to: Improve symptoms Reduce exacerbation frequency Optimise quality of life Oral Nebulised Intravenous used in bronchiectasis
26 Chronic bacterial suppression Concerns regarding: Antibiotic resistance Creating a niche for other bacteria / fungi Antibiotic related diarrhoea (C. difficile) Toxicity
27 Chronic bacterial suppression macrolides 141 patients 1 exacerbation Azith 500mg MWF 6/12 then 6/12 no Rx 83 patients 3 exacerbation Azith 250mg qid 12/12, 90/7 run out 117 patients 2 exacerbation Erythro 400mg bid 11/12, 1/12 wash out Wong Lancet 2012 Altenberg JAMA 2013 Serisier JAMA 2013
28 Chronic bacterial suppression other oral antibiotics MRC trial 1957 n=122 Oxytetracycline vs Penicillin vs Placebo 2 days / week for one year sputum volume / purulence time off work / days confined to bed MRC BMJ 1957
29 Chronic bacterial suppression inhaled antibiotics Benefits Very high drug concentrations within the airways Reduced systemic adverse effects Reduced risk of C. difficile Easy to administer
30 Chronic bacterial suppression inhaled antibiotics Predominantly for patients chronically infected with P. aeruginosa P. aeruginosa associated with: More severe lung disease Faster rate of lung function decline More admissions to hospital Increased mortality Worse quality of life Evans S ERJ 1996, Wilson C ERJ 1997, Miszkiel K Thorax 1997, Ho P-L Chest 1998, Martinez-Garcia M Chest 2007, Loebinger ERJ 2009
31 Chronic bacterial suppression inhaled antibiotics Impact of Pseudomonas Increased exacerbation frequency Increased hospitalisation Worse quality of life Faster rate of FEV 1 decline More severe disease Increased mortality Evans SA ERJ 1996 Wilson CB ERJ 1997 Miszkiel KA Thorax 1997 Ho-PL Chest 1998 Martinez-Garcia Chest 2007 Loebinger MR ERJ 2009 Chalmers AJRCCM 2014
32 Chronic bacterial suppression inhaled antibiotics Colistin: I-neb (Haworth et al ARJCCM 2014) AZLI no change in QoLB (Barker et al Lancet Resp Med 2014) Gentamicin - bacterial, exacerbations, QoL (Murray et al 2011 AJRCCM)
33 Chronic bacterial suppression inhaled antibiotics Colistin: I-neb (Haworth et al ARJCCM 2014) AZLI no change in QoLB (Barker et al Lancet Resp Med 2014) Gentamicin - bacterial, exacerbations, QoL (Murray et al 2011 AJRCCM)
34 Chronic bacterial suppression inhaled antibiotics Colistin: I-neb (Haworth et al ARJCCM 2014) AZLI no change in QoLB (Barker et al Lancet Resp Med 2014) Gentamicin - bacterial, exacerbations, QoL (Murray et al 2011 AJRCCM)
35 Chronic bacterial suppression inhaled antibiotics Colistin: I-neb (Haworth et al ARJCCM 2014) AZLI no change in QoLB (Barker et al Lancet Resp Med 2014) Gentamicin - bacterial, exacerbations, QoL (Murray et al 2011 AJRCCM)
36 Chronic bacterial suppression inhaled antibiotics Colistin: I-neb SGRQ QoL score (Haworth et al ARJCCM 2014) AZLI no change in QoLB (Barker et al Lancet Resp Med 2014) Gentamicin - bacterial, exacerbations, QoL (Murray et al 2011 AJRCCM)
37 Chronic bacterial suppression inhaled antibiotics Colistin: I-neb (Haworth et al ARJCCM 2014) Nebulized Aztreonam No change in QoL-B Adverse events ++ (Barker et al Lancet Resp Med 2014) Gentamicin - bacterial, exacerbations, QoL
38 Chronic bacterial suppression inhaled antibiotics Colistin: I-neb (Haworth et al ARJCCM 2014) Nebulized Aztreonam No change in QoL-B Adverse events ++ (Barker et al Lancet Resp Med 2014) Nebulized Gentamicin bacterial load, exacerbations, improved quality of life (Murray et al 2011 AJRCCM)
39 Chronic bacterial suppression inhaled antibiotics Ciprofloxacin Dry Powder Inhaler (Wilson ERJ 2013) Cipro Dual Release (Serisier 2013 Thorax)
40 Chronic bacterial suppression inhaled antibiotics Ciprofloxacin Dry Powder Inhaler (Wilson ERJ 2013) Nebulized Ciprofloxacin Dual Release Liposomal preparation (Serisier Thorax2013)
41 Current trials of inhaled antibiotics
42 Chronic bacterial suppression ERS guidelines Polverino Eur Resp J In press
43 Antibiotic use in Bronchiectasis Exacerbation treatment Chronic suppression Eradication
44 Pseudomonas aeruginosa eradication Randomised controlled trial 35 patients with new growths of Pseudomomas All patients received: Ceftazidime + Tobramycin for 2 weeks Randomised to: Neb TOBI 300mg or Placebo placebo 3 months Orriols Respiration 2015
45 Pseudomonas aeruginosa eradication Free of P. aeruginosa after 1 month: TOBI 91% Placebo 77% Free of P. aeruginosa after 12 months: TOBI 55% Placebo 29% p=0.048 Orriols Respiration 2015
46 Pseudomonas eradication ERS Guidelines Polverino Eur Resp J In press
47 Summary Antibiotic use in bronchiectasis Exacerbation treatment Chronic suppression Eradication
48 Acknowledgements CCLI Cambridge Centre for Lung Infection Andres Floto Helen Barker Nadia Shafi Chris Johnson Uta Hill Mike Harrison Helen Baxendale Nick Screaton Holly Bowles Olly Allen
Bronchiectasis exacerbations; differences and management. Michael Loebinger Royal Brompton Imperial College
Bronchiectasis exacerbations; differences and management Michael Loebinger Royal Brompton Imperial College Plan Bronchiectasis background and burden Exacerbation and Management Longer term Management Cases
Inhaled Antibiotics in Non-CF. Dr Michael Loebinger Host Defence Unit Royal Brompton Hospital London, United Kingdom
Inhaled Antibiotics in Non-CF Dr Michael Loebinger Host Defence Unit Royal Brompton Hospital London, United Kingdom Advantages Increased drug concentrations locally Reduced systemic adverse effects Home
How To Assess Severity and Prognosis
How To Assess Severity and Prognosis Gregory Tino, M.D. Chief, Department of Medicine Penn Presbyterian Medical Center Associate Professor of Medicine Perelman School of Medicine at the University of Pennsylvania
NON-CF BRONCHIECTASIS IN ADULTS
Séminaire de Pathologie Infectieuse Jeudi 25 juin 2008 Cliniques Universitaires UCL de Mont-Godinne, Yvoir NON-CF BRONCHIECTASIS IN ADULTS Dr Robert Wilson Royal Brompton Hospital, London, UK Aetiology
INHALED ANTIBIOTICS THERAPY IN NON-CF LUNG DISEASE
INHALED ANTIBIOTICS THERAPY IN NON-CF LUNG DISEASE Hannah Blau MBBS Pulmonary Institute and Graub CF Center SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL Chipap 18 th February 2015 Inhaled antibiotic therapy:
Bronchiectasis it s effects on the NZ population and what we can do to address this
NZ Respiratory Conference - 2017 Bronchiectasis it s effects on the NZ population and what we can do to address this Conroy Wong Middlemore Hospital Auckland, NZ Bronchiectasis in NZ and new developments
Dr Conroy Wong. Professor Richard Beasley. Dr Sarah Mooney. Professor Innes Asher
Professor Richard Beasley University of Otago Director Medical Research Institute of New Zealand Wellington Dr Sarah Mooney Physiotherapy Advanced Clinician Counties Manukau Health NZ Respiratory and Sleep
Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis
Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis Vallières, E., Tumelty, K., Tunney, M. M., Hannah, R., Hewitt, O., Elborn, J. S., & Downey, D. G. (2017). Efficacy of Pseudomonas
Conference Bronchiectasis A Growing Problem
Conference 2015 Bronchiectasis A Growing Problem Bronchiectasis (in Children) What is it? Why such a concern in NZ? What to look out for? Management Positives? Just a note that the bar for diagnosis, referral
Bronchiectasis. Introduction. Key points
15 Bronchiectasis Introduction i Key points Patients with bronchiectasis typically have chronic airway infection, punctuated by acute exacerbations and accompanied by progressive airflow obstruction. Bronchiectasis
Bronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh
Bronchiectasis Domiciliary treatment Prof. Adam Hill Royal Infirmary and University of Edinburgh Plan of talk Background of bronchiectasis Who requires IV antibiotics Domiciliary treatment Results to date.
The management of bronchiectasis in Europe
The management of bronchiectasis in Europe Data from the European Bronchiectasis Registry James Chalmers University of Dundee, UK Presenter disclosures Clinical Trials AstraZeneca, Aradigm corporation,
Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review
ORIGINAL ARTICLE BRONCHIECTASIS Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review Alessandra Monteiro Brodt 1, Elizabeth Stovold 2 and Linjie Zhang 1 Affiliations:
Management of bronchiectasis in adults
STATE OF THE ART MANAGEMENT OF BRONCHIECTASIS IN ADULTS Management of bronchiectasis in adults James D. Chalmers 1, Stefano Aliberti 2 and Francesco Blasi 3 Affiliations: 1 Tayside Respiratory Research
C.S. HAWORTH 1, A. WANNER 2, J. FROEHLICH 3, T. O'NEAL 3, A. DAVIS 4, I. GONDA 3, A. O'DONNELL 5
Inhaled Liposomal Ciprofloxacin in Patients With Non-Cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa: Results From Two Parallel Phase III Trials (ORBIT-3 and -4) C.S. HAWORTH 1, A. WANNER
NON-CYSTIC FIBROSIS BRONCHIECTASIS
NON-CYSTIC FIBROSIS BRONCHIECTASIS MARK L. METERSKY, MD PROFESSOR OF MEDICINE UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE FARMINGTON, CT Mark Metersky, MD, FCCP, FACP is a Professor of Medicine at the
Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing
National Institute for Health and Care Excellence Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing Evidence review NICE guideline NG117 December 2018 Disclaimer The
Bronchiectasis. What is bronchiectasis? What causes bronchiectasis?
This factsheet explains what bronchiectasis is, what causes it, and how it is diagnosed and managed. More detailed information is available on the Bronchiectasis Patient Priorities website: www.europeanlunginfo.org/bronchiectasis
Bronchiectasis. Grant Waterer. Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago
Bronchiectasis Grant Waterer MBBS PhD MBA FRACP FCCP Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago Conflicts of Interest I have
Palliative and Supportive Care in Cystic Fibrosis
Palliative and Supportive Care in Cystic Fibrosis Dr William Flight Consultant in Respiratory Medicine Oxford Adult Cystic Fibrosis Centre 27 th January 2017 Overview 1. Cystic Fibrosis Clinical Aspects
Inhaled antibiotics to treat NTM* lung infections
Inhaled antibiotics to treat NTM* lung infections *Nontuberculous Mycobacteria Lung Infection October 17, 2017 thofmann@qrumpharma.com Topics Why inhaled abx? - History in TB/NTM - Obstacles - Challenges
Navigating the Hills and Valleys of CF Lung Disease: Treating Disease
This Web cast has 2 parts: Part 1 Keeping Lungs Healthy Part 2 Treating Disease Navigating the Hills and Valleys of CF Lung Disease: Treating Disease This Web cast is supported by an unrestricted educational
Pulmonary Exacerbations:
Pulmonary Exacerbations: Better Understanding Needed Michael Tracy, MD Clinical Assistant Professor Pediatric Pulmonary CF Pulmonary Exacerbations Definition Importance Causes Treatment Research opportunities
Shared Care Guideline
Shared Care Guideline Gentamicin for Nebulisation For the long term prophylaxis of chronic lung infections in non CF bronchiectasis Executive Summary Indication Nebulised gentamicin is indicated in patients
COPD Bronchiectasis Overlap Syndrome.
COPD Bronchiectasis Overlap Syndrome. John R Hurst 1, J Stuart Elborn 2, and Anthony De Soyza 3 on Behalf of the BRONCH-UK Consortium (D Bilton, J Bradley, JS Brown, J Duckers, F Copeland, A Floto, J Foweraker,
Cystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina
Cystic Fibrosis: Progress in Treatment Management Patrick A. Flume, M.D. Medical University of South Carolina Disclosures Grant support Mpex Pharmaceuticals, Inc Gilead Sciences, Inc Bayer Healthcare AG
Journal Club The ELITE Trial. Sandra Katalinic, Pharmacy Resident University Hospital of Northern British Columbia April 28, 2010
Journal Club The ELITE Trial Sandra Katalinic, Pharmacy Resident University Hospital of Northern British Columbia April 28, 2010 Overview Journal article Title, journal, authors, funding Abstract Introduction
COPD Treatable. Preventable.
My COPD Action Plan Patient s Copy (Patient s Name) Date Canadian Respiratory COPD Treatable. Preventable. This is to tell me how I will take care of myself when I have a COPD flare-up. My goals are My
Cystic fibrosis: From childhood to adulthood. Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel
Cystic fibrosis: From childhood to adulthood Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel Vas deference H 2 O Cl - Na + H 2 O Na + Cl - Cl - Cl -
Cystic Fibrosis the future
Cystic Fibrosis the future Pathophysiologic cascade Abnormal Gene Abnormal CFTR Therapy Gene replacement Protein replacement Gene read through therapy Abnormal sodium chloride & water movement through
LRI Children s Hospital
Title: Prescribing in Cystic Fibrosis Page 1 of 10 LRI Children s Hospital Prescribing in Cystic Fibrosis Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team & AWP approval
Assessing response to treatment of exacerbations of bronchiectasis in adults
Eur Respir J 2009; 33: 312 317 DOI: 10.1183/09031936.00122508 CopyrightßERS Journals Ltd 2009 Assessing response to treatment of exacerbations of bronchiectasis in adults M.P. Murray, K. Turnbull, S. MacQuarrie
JUERGEN FROEHLICH, JANICE DAHMS, DAVID CIPOLLA,
Reduction in Frequency of Pulmonary Exacerbations With Inhaled ARD-315 in Non-Cystic Fibrosis Bronchiectasis (NCFB) Patients is Independent of Pseudomonas aeruginosa Susceptibility at Baseline JUERGEN
Treatment of lung infection in patients with cystic fibrosis: Current and future strategies,
Journal of Cystic Fibrosis 11 (2012) 461 479 www.elsevier.com/locate/jcf Review Treatment of lung infection in patients with cystic fibrosis: Current and future strategies, Gerd Döring a,, Patrick Flume
Fraser Health pandemic preparedness
Fraser Health pandemic preparedness DRAFT Last revised: April 2006 General Management of Patients in Acute Care Facilities During an Influenza Pandemic 1. OVERVIEW GENERAL MANAGEMENT OF PATIENTS IN ACUTE
Non-cystic fibrosis bronchiectasis
Non-cystic fibrosis bronchiectasis Maeve P Murray MB ChB MRCP, Clinical Research Fellow Adam T Hill MB ChB MD FRCPE, Consultant Respiratory Physician and Honorary Senior Lecturer Department of Respiratory
New Medicine Assessment
September 2015 New Medicine Assessment Colistimethate sodium/colistin sulfomethate sodium (Colomycin ) Non-Cystic Fibrosis in Patients with Bronchiectasis Colonised with Pseudomonas Aeruginosa Recommendation:
Non-CF bronchiectasis: Alexander Duarte, MD Pulmonary, Critical Care & Sleep Medicine University of Texas Medical Branch Galveston, TX
Non-CF bronchiectasis: Alexander Duarte, MD Pulmonary, Critical Care & Sleep Medicine University of Texas Medical Branch Galveston, TX Pioneer of Respiratory Medicine 2016 marked 200th anniversary of his
Understanding the heterogeneity of the disease
Symposium: Bronchiectasis in Europe: an update from the European Bronchiectasis Network (EMBARC) Understanding the heterogeneity of the disease Stefano Aliberti Health Science Department University of
Bronchiectasis in Adults - Suspected
Bronchiectasis in Adults - Suspected Clinical symptoms which may indicate bronchiectasis for patients Take full respiratory history including presenting symptoms, past medical & family history Factors
National Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008
Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
CYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions
CYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions Issue 1: Hypertonic Saline Summary: Preserving lung function is a crucial element in the care of the individual with
Pseudomonas aeruginosa eradication guideline
SCOTTISH PAEDIATRIC CYSTIC FIBROSIS MCN Pseudomonas aeruginosa eradication guideline Date Created: 27 th June 2013 Date Approved by Steering Group: 30 th May 2014 Date of Review: 31 st May 2016 Lead Author:
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
Eradication regimens for early or recurrent Pseudomonas aeruginosa infection
Eradication regimens for early or recurrent Pseudomonas aeruginosa infection The Leeds Method of Management. April, 2008. Cystic fibrosis and eradication therapy for early or recurrent Pseudomonas aeruginosa
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What
COPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK
COPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK Presenter Disclosures Wisia Wedzicha All disclosures prior
COPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
Appendix D Clinical specialist statement template
Appendix D Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of pseudomonas lung infection in cystic fibrosis Thank you for agreeing to give us a statement on your organisation
Guideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration
ERJ Express. Published on June 10, 2016 as doi: 10.1183/13993003.01888-2015 TASK FORCE REPORT IN PRESS CORRECTED PROOF Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical
Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing
National Institute for Health and Care Excellence Final Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing Evidence review December 2018 Contents Disclaimer The recommendations
C hronic obstructive pulmonary disease (COPD) is one of
589 RESPIRATORY INFECTIONS Time course of recovery of health status following an infective exacerbation of chronic bronchitis S Spencer, P W Jones for the GLOBE Study Group... Thorax 2003;58:589 593 See
Marcos I. Restrepo, MD, MSc, FCCP
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
Do processing time and storage of sputum influence quantitative bacteriology in bronchiectasis?
Journal of Medical Microbiology (), 59, 89 833 DOI.99/jmm..6683- Do processing time and storage of sputum influence quantitative bacteriology in bronchiectasis? Maeve P. Murray, Catherine J. Doherty, John
What is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF
What is Cystic Fibrosis? CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Chronic, progressive and life limiting autosomal recessive genetic disease characterized by chronic
Inhalational antibacterial regimens in non-cystic fibrosis patients. Jeff Alder Bayer HealthCare
Inhalational antibacterial regimens in non-cystic fibrosis patients Jeff Alder Bayer HealthCare Alder - Inhaled therapy for non-cf - EMA 25-26 Oct 2012 1 Inhalational antibacterials: two approaches 1.
The team. Medical staff Dr Adam Hill Vacant post- Dr Lithgow Dr Ruzanna Frangulyan Specialist Trainee
Bronchiectasis The team Medical staff Dr Adam Hill Vacant post- Dr Lithgow Dr Ruzanna Frangulyan Specialist Trainee Specialist staff Kim Turnbull Denise Gillian Jenny Scott Jo Pentland Research nurses
TRANSPARENCY COMMITTEE OPINION. 15 October Date of Marketing Authorisation (national procedure): 16 April 1997, variation of 18 February 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 October 2008 MERONEM 1 g, powder for solution for IV Injection Box of 10 vials (CIP: 387 830-6) Applicant: ASTRAZENECA
Effect of sputum bacteriology on the quality of life of patients with bronchiectasis
Eur Respir J 1997; 10: 1754 1760 DOI: 10.1183/09031936.97.10081754 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Effect of sputum bacteriology
Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
Hospital-acquired Pneumonia
Hospital-acquired Pneumonia Hospital-acquired pneumonia (HAP) Pneumonia that occurs at least 2 days after hospital admission. The second most common and the leading cause of death due to hospital-acquired
(cilia) that help sweep away fluids and/or particles International Journal of Pharmaceutical Sciences and Research 2055
IJPSR (2014), Vol. 5, Issue 5 (Research Article) Received on 29 November, 2013; received in revised form, 21 February, 2014; accepted, 16 April, 2014; published 01 May, 2014 EVALUATION OF EFFICACY AND
Antibiotics, Expectorants, and Cough Suppressants. Center For Cardiac Fitness Pulmonary Rehab The Miriam Hospital
Antibiotics, Expectorants, and Cough Suppressants Center For Cardiac Fitness Pulmonary Rehab The Miriam Hospital Objectives Review the mechanism of action (MOA), dosing, benefits, and various options for:
Early Pseudomonas Infection Control (EPIC) Clinical Study. Overview for Families
Early Pseudomonas Infection Control (EPIC) Clinical Study Overview for Families What is the EPIC Clinical Study? The EPIC Clinical Study Compares different treatments for children with CF who have just
The Bacteriology of Bronchiectasis in Australian Indigenous children
The Bacteriology of Bronchiectasis in Australian Indigenous children Kim Hare, Amanda Leach, Peter Morris, Heidi Smith-Vaughan, Anne Chang Presentation outline What is bronchiectasis? Our research at Menzies
Nebulised anti-pseudomonal antibiotics for cystic fibrosis (Review)
Nebulised anti-pseudomonal antibiotics for cystic fibrosis (Review) Ryan G, Mukhopadhyay S, Singh M This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published
CAP, HCAP, HAP, VAP. 1. In 1898, William Osler described community-acquired pneumonia as:
1. In 1898, William Osler described community-acquired pneumonia as: Brad Sharpe, M.D. Professor of Clinical Medicine Department of Medicine UCSF sharpeb@medicine.ucsf.edu I have no relevant financial
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH
Experience the Powder of Non-nebulized Pa Treatment
For people 6 years and older with cystic fibrosis (CF), Pseudomonas aeruginosa (Pa), and FEV 1 25% to 80% predicted and who do not have Burkholderia cepacia. Experience the Powder of Non-nebulized Pa Treatment
POLICY FOR TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS
POLICY F TREATMENT OF LOWER RESPIRATY TRACT INFECTIONS Written by: Dr M Milupi, Consultant Microbiologist Date: June 2018 Approved by: The Drugs & Therapeutics Committee Date: July 2018 Implementation
Fungal (Aspergillus and Candida) infections in Cystic fibrosis
Fungal (Aspergillus and Candida) infections in Cystic fibrosis Malena Cohen-Cymberknoh, MD CF Center Hadassah-Hebrew University Medical Center Jerusalem, Israel Israeli Annual CF Conference, Herzlyia,
Clinical Commissioning Policy Proposition: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (Adults)
Clinical Commissioning Policy Proposition: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (Adults) Reference: NHS England 1621 First published: Month Year Prepared
Clinical Commissioning Policy Proposition: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages)
Clinical Commissioning Policy Proposition: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages) Reference: NHS England E03X05/01 Information Reader Box (IRB) to be inserted on inside
Update on bronchiectasis guidelines. James Chalmers MD, PhD, FRCPE, FERS University of Dundee, UK
Update on bronchiectasis guidelines James Chalmers MD, PhD, FRCPE, FERS University of Dundee, UK University of Dundee Bronchiectasis guidelines 2017 2010 2006 2008 2015 2015 Currently valid guidelines
Francesco Blasi Head Respiratory Medicine Section Cardio-Thoracic Department University of Milan, Italy
COPD EXACERBATIONS Francesco Blasi Head Respiratory Medicine Section Cardio-Thoracic Department University of Milan, Italy COPD OUTCOMES Cazzola M et al. ERJ 2008 COPD AND CARDIOVASCULAR DISEASE Cumulative
an inflammation of the bronchial tubes
BRONCHITIS DEFINITION Bronchitis is an inflammation of the bronchial tubes (or bronchi), which are the air passages that extend from the trachea into the small airways and alveoli. Triggers may be infectious
10/05/2017. Learning Objectives. Etiology and Prevalence. Diagnosis of Cystic Fibrosis. Disease of Childhood? Survival in Cystic Fibrosis
Management of the Cystic Fibrosis Patient Jessica Goggin, MAS, RN Nurse Manager UC San Diego Adult Cystic Fibrosis Program Learning Objectives 1. Describe the symptoms associated with Cystic Fibrosis (CF).
Clinical Commissioning Policy: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages)
Clinical Commissioning Policy: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages) Reference: NHS England: 16029/P NHS England INFORMATION READER BOX Directorate Medical Operations and
The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis
ERJ Express. Published on August 9, 2006 as doi: 10.1183/09031936.06.00074605 The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis Davies G +, Wells AU*, Doffman S
Background. Background. Background 3/14/2014. Conflict of Interest Statement:
Platform Presentations Comparison of zolpidem to other drugs associated with falls in hospitalized patients Ed Rainville, MSPharm. Conflict of Interest Statement: The speaker has no conflict of interest
the potentially harmful nature of these secretions3 s even when given in the apparently stable clinical state.
Thorax 1986;41:559-65 Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation SL HILL, HM MORRISON, D BURNETT, RA STOCKLEY
Cystic Fibrosis: Pulmonary Exacerbations Management Guidelines
Cystic Fibrosis: Pulmonary Exacerbations Management Guidelines Inclusion Criteria: Age 1 year with cystic fibrosis admitted for a pulmonary exacerbation. Exclusion Criteria: ICU Admission Newborn with
A Place For Airway Clearance Therapy In Today s Healthcare Environment
A Place For Airway Clearance Therapy In Today s Healthcare Environment Michigan Society for Respiratory Care 2015 Fall Conference K. James Ehlen, MD October 6, 2015 Objectives Describe patients who will
Long-term antibiotics in the management of non-cf bronchiectasisfdo they improve outcome?
Respiratory Medicine (2003) 97, 851 858 Long-term antibiotics in the management of non-cf bronchiectasisfdo they improve outcome? D.J. Evans a, *, M. Greenstone b a Hemel Hempstead Hospital, Hillfield
COPD exacerbation. Dr. med. Frank Rassouli
Definition according to GOLD report: - «An acute event - characterized by a worsening of the patients respiratory symptoms - that is beyond normal day-to-day variations - and leads to a change in medication»
Clinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (all ages)
Clinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (all ages) NHS England Reference: 1732P NHS England INFORMATION READER BOX Directorate
Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis 5/01/2011 CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN.
1938 OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN. American Journal Diseases Children. : The beginning May 1938: 49 cases 25 20 15 Nos of cases 10 5 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 Age
Arnold L. Smith, MD; Stanley B. Fiel, MD, FCCP; Nicole Mayer-Hamblett, PhD; Bonnie Ramsey, MD; and Jane L. Burns, MD
Susceptibility Testing of Pseudomonas aeruginosa Isolates and Clinical Response to Parenteral Antibiotic Administration Lack of Association in Cystic Fibrosis Arnold L. Smith, MD; Stanley B. Fiel, MD,
Nebulised tobramycin for cystic fibrosis. Information for patients Pharmacy
Nebulised tobramycin for cystic fibrosis Information for patients Pharmacy This leaflet has been made to give you some more information to help you with your treatment. Please also read the manufacturers
Management of URTI s in Children
Management of URTI s in Children Robin J Green PhD Antibiotics - Dilemmas for General Practitioners Antibiotic overuse = Resistance Delay in antibiotic use = Mortality Patient expectation Employer expectation
Clinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Goyal V, Grimwood K, Byrnes CA, et al. Amoxicillin
Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis
Eur Respir J 2002; 20: 122 126 DOI: 10.1183/09031936.02.00264002 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Bronchial reactions to the
Advances in the Management of Empyema
Advances in the Management of Empyema RCP Update in Respiratory Medicine 26 th January 2017 Najib M Rahman Associate Professor of Respiratory Medicine University of Oxford najib.rahman@ndm.ox.ac.uk Financial
Deep discoveries: the ED. Brian H. Rowe, MD, MSc, CCFP(EM) Canada Research Chair in Emergency Airway Diseases Department of Emergency Medicine
Deep discoveries: Treating respiratory infections in the ED. Brian H. Rowe, MD, MSc, CCFP(EM) Canada Research Chair in Emergency Airway Diseases Department of Emergency Medicine University of Alberta Respiratory
The Role of Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
...SYMPOSIUM PROCEEDINGS... The Role of Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease Robert E. Hillberg, MD Presentation Summary Chronic obstructive pulmonary disease (COPD)
Pneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
Respiratory Research Newsletter
Date Published: September 2012 Respiratory Research Newsletter Contents Research at the Belfast Trust 1 NICRN Respiratory Health 2 The Respiratory Research Team 3 Our Partners 4 Getting Involved in Upcoming
Role of long term antibiotics in chronic respiratory diseases
Respiratory Medicine (2013) xx, 1e16 + MODEL Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed REVIEW Role of long term antibiotics in chronic respiratory diseases